Howland Capital Management LLC trimmed its stake in Johnson & Johnson (NYSE:JNJ) by 0.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 208,258 shares of the company’s stock after selling 1,137 shares during the period. Johnson & Johnson accounts for about 2.2% of Howland Capital Management LLC’s investment portfolio, making the stock its 7th largest position. Howland Capital Management LLC’s holdings in Johnson & Johnson were worth $27,076,000 as of its most recent filing with the SEC.

Several other hedge funds also recently modified their holdings of JNJ. Harding Loevner LP bought a new position in Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Lenox Wealth Advisors Inc. grew its holdings in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after purchasing an additional 5 shares in the last quarter. IHT Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 46.4% during the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $124,000. 65.71% of the stock is currently owned by institutional investors and hedge funds.

Shares of Johnson & Johnson (NYSE:JNJ) opened at $146.92 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. The company has a market capitalization of $394,864.69, a price-to-earnings ratio of 25.51, a P/E/G ratio of 2.75 and a beta of 0.80. Johnson & Johnson has a one year low of $110.76 and a one year high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The business had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.68 EPS. equities analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.29%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is 58.33%.

Several brokerages have recently weighed in on JNJ. Wells Fargo & Co reissued an “outperform” rating and set a $160.00 price objective (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday, January 12th. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price objective on the stock in a report on Thursday, January 11th. Royal Bank of Canada reissued a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 2nd. Finally, BMO Capital Markets lifted their price objective on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company. Johnson & Johnson presently has an average rating of “Hold” and a consensus price target of $145.94.

COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-shares-sold-by-howland-capital-management-llc/1813439.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.